# Before starting tirzepatide: the decisions that matter

Understand the treatment goal, medical review, side effects, reproductive considerations and follow-up before starting tirzepatide.

Canonical: https://velri.co/blog/results-driven-owner-dual-action-glp1-questions-before-starting
Publisher: Velri (https://velri.co/about)
Published: 2026-06-17
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

Before starting tirzepatide, the useful question is whether the proposed treatment fits the person's medical needs and circumstances. “Strongest” is not a complete description of a medication: expected benefit, tolerability and safety all affect the decision. [1]

Tirzepatide acts at GIP and GLP-1 receptors. Those names explain its mechanism, but they do not establish that it is the right option for every person seeking weight management. [1]

## Define the reason for treatment

A prescribing discussion should identify the condition being treated and the outcomes that will be reviewed over time. The approved injection's label includes eligibility criteria and clinical-trial populations. Those details matter more than comparing isolated results from people with different starting points. [1]

A clear plan also identifies who reviews progress, how new symptoms are reported and what happens if the treatment is not tolerated.

## Review more than the medication list

Relevant history includes serious allergic reactions, severe stomach-emptying problems and a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. The label includes contraindications and warnings that make these specific facts important. [1]

Nausea, vomiting, diarrhea and constipation are among the possible adverse effects. Persistent vomiting or diarrhea can contribute to dehydration; severe or persistent symptoms should not be treated as proof that the medication is working. [1]

## Include pregnancy and contraception

Pregnancy plans, breastfeeding and contraception belong in the initial review. Tirzepatide can affect the effectiveness of oral hormonal contraception, and its label specifies additional precautions around initiation and dose increases. The prescribing provider should explain the applicable plan. [1]

## Know which product is being prescribed

A compounded preparation is not an FDA-approved generic or an interchangeable version of a branded drug. FDA does not review compounded drugs for safety, effectiveness or quality before marketing. [2]

The exact product, pharmacy, follow-up arrangements and full payment terms should be understandable before treatment begins. Those are concrete decisions a promotional comparison cannot make.

## Sources
[1] DailyMed - ZEPBOUND- tirzepatide injection, solution
ZEPBOUND- tirzepatide injection, solution
ZEPBOUND KWIKPEN- tirzepatide injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
[2] Compounding and the FDA: Questions and Answers | FDA. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support